MX2016014643A - Composiciones de insulina de rapida accion. - Google Patents

Composiciones de insulina de rapida accion.

Info

Publication number
MX2016014643A
MX2016014643A MX2016014643A MX2016014643A MX2016014643A MX 2016014643 A MX2016014643 A MX 2016014643A MX 2016014643 A MX2016014643 A MX 2016014643A MX 2016014643 A MX2016014643 A MX 2016014643A MX 2016014643 A MX2016014643 A MX 2016014643A
Authority
MX
Mexico
Prior art keywords
action
insulin compositions
quick
quick insulin
insulin analog
Prior art date
Application number
MX2016014643A
Other languages
English (en)
Other versions
MX367521B (es
Inventor
Edward CHRISTE Michael
Andrew HARDY Thomas
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53189204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016014643(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2016014643A publication Critical patent/MX2016014643A/es
Publication of MX367521B publication Critical patent/MX367521B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición de insulina humana o análogo de insulina, que incluye treprostinil y que tiene acción de farmacocinética más rápida que las formulaciones comerciales de productos análogos de insulina existentes.
MX2016014643A 2014-05-08 2015-05-04 Composiciones de insulina de rápida acción. MX367521B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461990402P 2014-05-08 2014-05-08
PCT/US2015/029010 WO2015171484A1 (en) 2014-05-08 2015-05-04 Rapid-acting insulin compositions

Publications (2)

Publication Number Publication Date
MX2016014643A true MX2016014643A (es) 2017-03-06
MX367521B MX367521B (es) 2019-08-26

Family

ID=53189204

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014643A MX367521B (es) 2014-05-08 2015-05-04 Composiciones de insulina de rápida acción.

Country Status (36)

Country Link
US (2) US9439952B2 (es)
EP (3) EP3943155A1 (es)
JP (1) JP6050902B2 (es)
KR (1) KR101858890B1 (es)
CN (1) CN106456717B (es)
AP (1) AP2016009525A0 (es)
AR (1) AR100155A1 (es)
AU (1) AU2015256355B2 (es)
BR (1) BR112016024357B1 (es)
CA (1) CA2945188C (es)
CL (1) CL2016002772A1 (es)
CY (2) CY1121669T1 (es)
DK (2) DK3140008T3 (es)
EA (1) EA031134B1 (es)
ES (2) ES2891983T3 (es)
HR (2) HRP20190777T1 (es)
HU (2) HUE055742T2 (es)
IL (1) IL248350B (es)
JO (1) JO3624B1 (es)
LT (2) LT3140008T (es)
MA (1) MA39441A1 (es)
ME (1) ME03384B (es)
MX (1) MX367521B (es)
NZ (1) NZ724919A (es)
PE (1) PE20161408A1 (es)
PH (1) PH12016502195A1 (es)
PL (2) PL3536380T3 (es)
PT (2) PT3536380T (es)
RS (2) RS58726B1 (es)
SG (1) SG11201608424WA (es)
SI (2) SI3536380T1 (es)
TN (1) TN2016000443A1 (es)
TR (1) TR201906843T4 (es)
TW (1) TWI685348B (es)
UA (1) UA124919C2 (es)
WO (1) WO2015171484A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102037008B (zh) 2008-03-18 2016-08-31 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
ES2972423T3 (es) * 2015-07-28 2024-06-12 Lilly Co Eli Preparado farmacéutico para mejorar la absorción y la acción hipoglucemiante postprandial de la insulina
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
WO2017132601A1 (en) * 2016-01-29 2017-08-03 Mannkind Corporation Dry powder inhaler
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
JP7220650B2 (ja) 2016-09-26 2023-02-10 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
DK3518892T5 (da) 2016-09-29 2024-09-02 Arecor Ltd Farmaceutisk formulering, der indeholder en insulinforbindelse
TWI700091B (zh) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
KR20190140048A (ko) * 2017-06-01 2019-12-18 일라이 릴리 앤드 캄파니 신속-작용 인슐린 조성물
CA3094304A1 (en) * 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
IL277721B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
CN112040928A (zh) 2018-04-04 2020-12-04 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵系统
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
AU2019344541B2 (en) 2018-09-18 2022-01-06 Eli Lilly And Company Erbumine salt of treprostinil
US10799564B1 (en) * 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
JP2022546314A (ja) 2019-08-23 2022-11-04 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
AU2021255621A1 (en) 2020-04-17 2022-10-20 United Therapeutics Corporation Treprostinil for use in the treatment of intersitial lung disease
JP7608480B2 (ja) 2020-06-09 2025-01-06 ユナイテッド セラピューティクス コーポレイション トレプロスチニルのフマリルジケトピペリジンプロドラッグ
TW202214292A (zh) * 2020-06-30 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 速效胰島素組成物及其醫藥用途
WO2022132655A1 (en) 2020-12-14 2022-06-23 United Therapeutics Corporation Methods of treating disease with treprostinil prodrugs
AU2022229367A1 (en) 2021-03-03 2023-09-14 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
KR20250002687A (ko) * 2022-04-29 2025-01-07 자오커 파마슈티컬 (광저우) 컴퍼니., 리미티드 트레프로스티닐 소프트 미스트 흡입제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
JPH10251146A (ja) * 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
CA2452044A1 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
JP5599543B2 (ja) * 2002-05-07 2014-10-01 ノヴォ ノルディスク アー／エス 単量体インスリン及びアシル化インスリンを含む可溶性製剤
ATE462427T1 (de) * 2004-04-12 2010-04-15 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
EP2545920A1 (en) * 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
US9387033B2 (en) 2008-08-28 2016-07-12 Roche Diabetes Care, Inc. Device and method for enhanced subcutaneous insulin absorption
KR20110081204A (ko) * 2008-09-25 2011-07-13 아라다임 코포레이션 트레프로스티닐의 폐 심부 전달
AU2010264636B2 (en) * 2009-06-26 2013-06-27 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
KR101701943B1 (ko) * 2009-11-13 2017-02-02 도레이 카부시키가이샤 당뇨병의 치료 또는 예방약
MX2013006174A (es) 2010-12-14 2013-07-15 Novo Nordisk As Preparacion que comprende insulina, nicotinamida y un aminoacido.
MX349950B (es) * 2011-08-12 2017-08-22 Ascendis Pharma As Profarmacos de treprostinil enlazados a un portador.
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
WO2015120457A1 (en) 2014-02-10 2015-08-13 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations

Also Published As

Publication number Publication date
EP3140008A1 (en) 2017-03-15
CN106456717A (zh) 2017-02-22
EP3536380B8 (en) 2021-09-22
CA2945188A1 (en) 2015-11-12
DK3536380T3 (da) 2021-08-02
HUE055742T2 (hu) 2021-12-28
US9439952B2 (en) 2016-09-13
MA39441A1 (fr) 2017-06-30
EP3140008B1 (en) 2019-04-17
SI3140008T1 (sl) 2019-06-28
BR112016024357A2 (pt) 2017-10-10
IL248350A0 (en) 2016-11-30
PL3140008T3 (pl) 2019-09-30
ME03384B (me) 2020-01-20
IL248350B (en) 2020-03-31
CY1124454T1 (el) 2022-07-22
AR100155A1 (es) 2016-09-14
EP3536380A1 (en) 2019-09-11
LT3140008T (lt) 2019-05-27
UA124919C2 (uk) 2021-12-15
RS58726B1 (sr) 2019-06-28
US10172922B2 (en) 2019-01-08
KR101858890B1 (ko) 2018-05-16
PH12016502195B1 (en) 2017-02-06
WO2015171484A1 (en) 2015-11-12
ES2891983T3 (es) 2022-02-01
CY1121669T1 (el) 2020-07-31
RS62291B1 (sr) 2021-09-30
LT3536380T (lt) 2021-08-10
CL2016002772A1 (es) 2017-06-09
HUE044370T2 (hu) 2019-10-28
DK3140008T3 (da) 2019-06-24
SG11201608424WA (en) 2016-11-29
TR201906843T4 (tr) 2019-05-21
EA201691911A1 (ru) 2017-02-28
PT3140008T (pt) 2019-06-25
KR20160133567A (ko) 2016-11-22
EP3943155A1 (en) 2022-01-26
BR112016024357B1 (pt) 2022-08-23
US20160129087A1 (en) 2016-05-12
PH12016502195A1 (en) 2017-02-06
HRP20190777T1 (hr) 2019-08-23
US20160367640A1 (en) 2016-12-22
PT3536380T (pt) 2021-09-02
TW201625291A (zh) 2016-07-16
PL3536380T3 (pl) 2021-12-27
ES2733639T3 (es) 2019-12-02
JO3624B1 (ar) 2020-08-27
PE20161408A1 (es) 2016-12-28
CA2945188C (en) 2018-12-11
AU2015256355A1 (en) 2016-10-27
NZ724919A (en) 2018-01-26
TN2016000443A1 (en) 2018-04-04
HRP20211415T1 (hr) 2021-12-10
SI3536380T1 (sl) 2021-09-30
TWI685348B (zh) 2020-02-21
EA031134B1 (ru) 2018-11-30
AP2016009525A0 (en) 2016-10-31
AU2015256355B2 (en) 2017-09-14
JP6050902B2 (ja) 2016-12-21
JP2016523807A (ja) 2016-08-12
EP3536380B1 (en) 2021-07-07
CN106456717B (zh) 2020-01-17
MX367521B (es) 2019-08-26

Similar Documents

Publication Publication Date Title
MX2016014643A (es) Composiciones de insulina de rapida accion.
CL2023001909A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
ECSP18014922A (es) Composiciones de insulina de rápida acción
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
BR112017006137A2 (pt) formulação que contém biotensoativo
EP3099381A4 (en) Extended release fragrance compositions
BR112016028697A2 (pt) artigos que fornecem fragrâncias de longa duração
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
BR112016020181A2 (pt) Composições de ácido lipoico éster colina e métodos de uso.
BR112017009731A2 (pt) composição de limpeza
MX371443B (es) Composiciones farmaceuticas que comprenden levocetirizina.
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
MX373197B (es) Formulaciones estables de undecanoato de testosterona.
FI20150044A7 (fi) Rasvahappokoostumus
BR112017012524A2 (pt) composição contendo éster parcial de carboidrato
BR112017000228A2 (pt) polimixinas de baixa substituição e suas composições.
ECSP19085451A (es) Composiciones de insulina de rápida acción
CO2018001431A2 (es) 2,4,7-trimetiloct-6-en-1-ol como ingrediente de fragancia
MX382187B (es) Extracto concentrado de sabadilla.
CO6980660A2 (es) Composiciones que cambian de color

Legal Events

Date Code Title Description
FG Grant or registration